Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Consensus Target Price from Brokerages

Sutro Biopharma, Inc. (NASDAQ:STROGet Free Report) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.13.

A number of research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Sutro Biopharma in a research note on Monday, November 18th. Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, December 10th. Wells Fargo & Company dropped their price objective on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. JMP Securities reissued a “market outperform” rating and issued a $17.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Finally, Piper Sandler reissued an “overweight” rating and issued a $11.00 price objective on shares of Sutro Biopharma in a research note on Friday, October 11th.

Read Our Latest Research Report on STRO

Sutro Biopharma Price Performance

Shares of STRO stock opened at $1.99 on Friday. The company has a market cap of $164.09 million, a PE ratio of -1.24 and a beta of 1.15. The stock’s 50 day simple moving average is $2.29 and its two-hundred day simple moving average is $3.33. Sutro Biopharma has a 1 year low of $1.67 and a 1 year high of $6.13.

Institutional Trading of Sutro Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Gladius Capital Management LP purchased a new stake in shares of Sutro Biopharma during the 3rd quarter valued at $28,000. ProShare Advisors LLC lifted its holdings in shares of Sutro Biopharma by 49.1% during the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after purchasing an additional 5,373 shares during the last quarter. Virtu Financial LLC purchased a new position in Sutro Biopharma in the 3rd quarter worth $77,000. Intech Investment Management LLC purchased a new position in Sutro Biopharma in the 3rd quarter worth $91,000. Finally, The Manufacturers Life Insurance Company raised its stake in Sutro Biopharma by 27.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after acquiring an additional 7,082 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

(Get Free Report

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

Recommended Stories

Analyst Recommendations for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.